A phase II trial of active specific immunotherapy in patients with indolent lymphoma using autologous lymphoma-derived heat shock protein-peptide complex (HSPPC-96) [cancer vaccine HSPPC-96]

Trial Profile

A phase II trial of active specific immunotherapy in patients with indolent lymphoma using autologous lymphoma-derived heat shock protein-peptide complex (HSPPC-96) [cancer vaccine HSPPC-96]

Completed
Phase of Trial: Phase II

Latest Information Update: 07 Dec 2016

At a glance

  • Drugs Vitespen (Primary)
  • Indications Lymphoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 08 Nov 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top